The Carcinoid Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Carcinoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Carcinoid Tumor. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Carcinoid Tumor - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Carcinoid Tumor and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Carcinoid Tumor by eight companies/universities/institutes. The top development phase for Carcinoid Tumor is phase ii with three drugs in that stage. The Carcinoid Tumor pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Carcinoid Tumor pipeline products market are: Max Delbruck Center for Molecular Medicine, Loxo Oncology and Chiesi Farmaceutici.

The key targets in the Carcinoid Tumor pipeline products market include Somatostatin Receptor Type 2, Somatostatin Receptor, and Somatostatin Receptor Type 5.

The key mechanisms of action in the Carcinoid Tumor pipeline product include Somatostatin Receptor Agonist with two drugs in Phase II. The Carcinoid Tumor pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Carcinoid Tumor pipeline products market including Small Molecule, and Synthetic Peptide.

Carcinoid Tumor overview

Carcinoid tumors are slow-growing tumors arising from neuroendocrine cells and capable of secreting a variety of peptides and neuroamines. The common primary sites are the gastrointestinal (GI) tract, tracheobronchial tree, ovaries, and kidneys. The most common location of carcinoids is the small intestine. The term carcinoid is usually used for well-differentiated and low- to intermediate-grade neuroendocrine tumors.

For a complete picture of Carcinoid Tumor’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.